WIT DYNE(SZ:000915)2022-11-21 05:30Group 1: Financial Performance - The overall revenue and profit of Huate Dain in 2021 increased by approximately 30% year-on-year, with a significant growth of about 70% in the fourth quarter [2][4] - The net profit in the fourth quarter was relatively low due to the divestment of the environmental segment and increased investment in new product development [2][3] - The company’s revenue fluctuations are influenced by seasonal factors and e-commerce promotions, but overall operations remain stable [2][3] Group 2: Product Pricing and Market Strategy - Price adjustments for the product "Yikexin" began on January 1, 2022, with a slight increase for specific packaging sizes [3][4] - The company maintains a cautious approach to pricing, considering market conditions and consumer acceptance [3][4] - The penetration rate of "Yikexin" among children under 6 years old is low, with over 50% of this demographic lacking sufficient Vitamin A [4][5] Group 3: Future Growth and Product Development - Huate Dain has initiated a new strategy to expand the target demographic for "Yikexin" from 0-3 years to up to 6 years old [4][5] - The company is focusing on the development of new therapeutic drugs, with significant breakthroughs expected in pediatric medications [4][5] - The strategic partnership with Alibaba Health aims for a GMV target of 150 million yuan in 2022, with plans for further collaborations with other platforms [5][6] Group 4: Corporate Governance and Strategic Focus - The company has committed to focusing on its core pharmaceutical business, with plans to divest non-core assets as necessary [6] - The long-term incentive plan for Dain Pharmaceutical is based on stable growth from 2021 to 2025, with a requirement for continuous performance improvement [3][6] - The company’s minority equity is considered a high-quality and secure asset, with future acquisitions being prioritized [6]